30-day average of 20 articles ยท scale โ100 to +100
Across 20 scored articles from Oct 17 to Nov 15, 2026 (UTC),
the average sentiment of AbbVie news is Bullish (+51)
on a scale from โ100 to +100.
That is about the same as the previous 30 days (+53).
๐ค AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion.
Bullish +62
AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
AI-generated analysis
Key insights
๐ AbbVie shares surged over 23% year-to-date, outperforming the S&P 500's roughly 13% gain as investors assess its transition strategy.
๐ Skyrizi and Rinvoq drove immunology revenue to $8.79 billion (up 15.1%), with Skyrizi up 24.4% and Rinvoq up 24.5%, offsetting a 35.9% decline in Humira.
๐ง The neuroscience portfolio delivered strong growth, increasing revenue by 20.3% to $3.23 billion in the second quarter.
๐ค AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion to bolster its immunology pipeline with late-stage candidate zumilokibart.
๐ฐ The company reported total second-quarter revenue of $16.99 billion (up 10.2%) and adjusted diluted EPS rose 22.9% on a reported basis.
โ ๏ธ Management expects the Apogee acquisition to have a $0.14 per share dilutive impact on 2026 adjusted EPS, alongside an unfavorable $0.58-per-share impact from acquired IPR&D expenses.
๐ AbbVie's forward P/E is approximately 16.4x, significantly lower than its trailing P/E of 74.88x due to non-recurring acquisition-related items affecting reported earnings.
๐ฎ The company expects 2026 adjusted diluted EPS between $13.87 and $14.07, following a revision to its July outlook.
๐ Humira revenue fell 35.9% to $756 million in the second quarter as AbbVie continues its portfolio transition away from the aging blockbuster.
๐ The Apogee acquisition is expected to close in the third quarter of 2026, adding clinical-stage immunology assets to the pipeline.
๐ Bullish signals
๐AbbVie shares surged over 23% year-to-date, significantly outperforming the broader market's roughly 13% gain.
๐Skyrizi and Rinvoq generated combined immunology revenue of $8.79 billion (up 15.1%), with individual growth rates of 24.4% and 24.5% respectively, effectively offsetting the decline in Humira.
๐ง The neuroscience portfolio demonstrated robust expansion with revenue increasing 20.3% to $3.23 billion in the second quarter.
๐ฐTotal company revenue increased 10.2% on a reported basis to $16.99 billion in the second quarter, while adjusted diluted EPS rose 22.9%.
๐ Risk factors
๐Humira revenue fell 35.9% to $756 million in the second quarter as the company continues its transition away from the aging blockbuster.
โ ๏ธThe acquisition of Apogee Therapeutics for approximately $10.9 billion will have a dilutive impact on 2026 adjusted EPS, including an unfavorable $0.58-per-share impact from acquired IPR&D expenses and an additional $0.14 per share dilution from the deal itself.
๐AbbVie's trailing P/E ratio is nearly 75x (74.88x), significantly higher than its forward P/E of 16.4x, indicating that reported earnings are currently depressed by significant acquisition-related and other specified items.
Article
AbbVie (NYSE: ABBV) has delivered strong returns in the first half of 2026, with shares surging over 23% year-to-date, significantly outperforming the broader market's roughly 13% gain. The company is currently trading at a forward P/E of approximately 16.4x, which analysts view as reasonable given its growth trajectory, though this contrasts sharply with its trailing P/E of nearly 75x due to significant acquisition-related and other specified items affecting reported earnings.
The core investment thesis for AbbVie centers on its ability to successfully transition away from the declining blockbuster Humira, which saw revenue fall 35.9% in the second quarter to $756 million. This decline has been effectively offset by robust growth in its newer immunology franchises: Skyrizi generated $5.505 billion (up 24.4%) and Rinvoq generated $2.53 billion (up 24.5%), bringing total global net revenue from the immunology portfolio to $8.79 billion, a 15.1% increase.
Beyond immunology, AbbVie's neuroscience portfolio showed particular strength with revenue increasing 20.3% to $3.23 billion in the second quarter. The company is also executing a major strategic expansion by acquiring Apogee Therapeutics for approximately $10.9 billion to add late-stage clinical assets like zumilokibart, expected to close in the third quarter of 2026. However, this acquisition and ongoing pipeline investment will have a dilutive impact on adjusted EPS, with management expecting an unfavorable $0.58-per-share impact from acquired IPR&D expenses and an additional $0.14 per share dilution from the Apogee deal itself.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Bank of America upgraded AbbVie (ABBV) to a Buy rating from Neutral on Thursday, April 30, driven by the belief that fears regarding competition are overdone and that the company's premium valuation is warranted by its growth profile and durable pipeline. Analysts at the firm cited three primary reasons for the upgrade: ABBV's multiple looks justified given its top-tier growth relative to peers with limited identifiable headwinds in the next seven years; strong and durable growth prospects in its core immunology brands despite increasing competition; and significant upside potential tied to recent pipeline efforts. This move highlights a shift from defensive positioning toward a more bullish view on the biotech giant's long-term value proposition.
The upgrade contrasts with other analyst activity on the day, such as JPMorgan downgrading Meta due to intensifying AI competition concerns, though Wells Fargo maintained an overweight rating on the same company citing robust ad growth and potential for future catalysts. While the broader market saw mixed signals across technology, including Bank of America raising its price target for Amazon and JPMorgan upgrading Teradyne, the specific focus on AbbVie in this analyst roundup underscores confidence in its pharmaceutical portfolio against competitors like Regeneron and potentially emerging biologic rivals. The upgrade implies that investors should view ABBV's growth trajectory as sustainable beyond immediate market pressures, particularly in its top-selling immunology drugs like Humira biosimilars where it maintains a lead through patent extensions or new formulations.
The article itself aggregates these analyst calls from major financial institutions including Raymond James, Deutsche Bank, and Morgan Stanley, covering a wide range of sectors from semiconductor stocks like Nvidia and Qualcomm to cloud computing leaders such as Microsoft and Google. While AbbVie is one of many companies discussed in this Thursday briefing, the Bank of America upgrade serves as a notable positive development for the stock, suggesting that Wall Street is beginning to discount competition risks more favorably than previously priced in during the second quarter of fiscal year 2026.
๐ Analysts upgrade Equinix, Palantir, and Microsoft citing strong AI demand and growth.
๐ JPMorgan raises Alphabet target while downgrading Meta over intensifying AI competition.
๐ Bank of America upgrades AbbVie, Nutrien, and Amazon on earnings strength.
๐ Raymond James upgrades Equinix (EQIX) from outperform to strong buy following Q1 2026 results and AI-based demand.
๐ง Deutsche Bank upgrades SiteOne Landscape to buy, citing a low valuation that implies 32% upside from their $160 price target.
๐ก๏ธ Roth Capital initiates coverage on Mistras with a buy rating and $22 price target due to improved operating efficiency.
๐ค Bank of America reiterates Nvidia (NVDA) as a buy, maintaining a $300 price target based on 28x CY27E PE.
๐ป Oppenheimer initiates coverage of Palantir (PLTR) with an outperform rating and $200 price target.
๐ Baird upgrades Blackbaud to outperform from neutral after a solid Q1 beat and steady customer retention.
๐ JPMorgan upgrades Teradyne to overweight following a stock pullback driven by lumpiness in customer purchasing.
โ ๏ธ JPMorgan downgrades Meta (META) from overweight to neutral due to intensifying full-stack AI competition.
๐พ Bank of America upgrades Nutrien to buy, viewing the agriculture market as increasingly bullish.
๐ Bank of America upgrades AbbVie (ABBV) to buy from neutral, dismissing competition fears and citing strong immunology brand growth.
โ๏ธ Morgan Stanley reiterates Microsoft as overweight, praising agentic computing expansion and AI-driven margin improvements.
๐ Bank of America raises its Amazon price target to $310 from $298 following earnings on strong eCommerce and cloud assets.
๐ JPMorgan raises Alphabet's price target to $460 from $395, citing clear returns on AI investments and doubled cloud backlog.
๐ฐ Wells Fargo reiterates Meta as overweight, noting robust ad growth despite macro headwinds in the Middle East.
๐ฑ Qualcomm receives a neutral hold from JPMorgan due to Q2 earnings beat but weak Q3 guidance influenced by smartphone headwinds.
Bullish Signals
Bank of America upgrades AbbVie (ABBV) to Buy.
Growth warrants a premium multiple near top peers.
Core immunology brands show strong and durable prospects.
Limited portfolio headwinds identified for the next 7 years.
Risk Factors
JPMorgan downgraded Meta as AI costs pressure returns amid competition.
Wells Fargo says Meta growth catalysts are delayed to next year.
Qualcomm missed guidance due to smartphone headwinds and shipment concerns.
Middle East conflict hurts Meta ad growth while product rollout delays.
Bullish Signals
Bank of America upgrades AbbVie to a Buy from Neutral, signaling confidence that competition fears are overdone.
Analysts at Bank of America rate ABBV as having a premium multiple well warranted given growth near the top of the peer group.
The firm sees strong and durable growth prospects in core immunology brands despite increasing competition.
There is significant upside potential tied to AbbVie's robust pipeline efforts according to Bank of America.
Bank of America identifies limited identifiable portfolio headwinds in the next 7 years for the stock.
Risk Factors
JPMorgan downgraded Meta from overweight to neutral due to rising competition and concerns that a full-stack AI intensifies pressure, making it harder for Meta to generate returns on heavy AI capital expenditures.
Wells Fargo noted that product catalysts for Meta seem pushed to the second half of the year, delaying the path to aggressive growth while operating expense ramp-up continues.
JPMorgan raised concerns about Qualcomm facing headwinds in the smartphone industry that drove its third-quarter guidance to track below consensus, partly due to expectations of another quarter of under-shipping relative to end customers.
The outlook for Meta includes macro headwinds related to the Middle East conflict impacting ad growth, with product catalysts delayed until later in the year.
AbbVie Inc. reported first-quarter 2026 results that significantly exceeded analyst expectations, with adjusted earnings per share (EPS) of $2.65 and total net revenues reaching $15.0 billion, representing a 12.4% increase year-over-year. CEO Rob Michael described the performance as exceeding expectations across the diverse portfolio, while CFO Scott Reents highlighted an adjusted EPS that was $0.07 above the midpoint of guidance. Notably, Reents specified that the first-quarter results included a $0.41 unfavorable impact from acquired in-process R&D expenses. Consequently, the company raised its full-year adjusted EPS guidance by $0.12 to a range of $14.08โ$14.28 and updated expectations for 2026 total net revenues to approximately $67.3 billion.
The primary driver of this commercial momentum was the strong performance within immunology, where SKYRIZI and RINVOQ posted substantial growth. SKYRIZI achieved global sales of $4.5 billion, a 29% operational increase, fueled by demand in psoriatic and inflammatory bowel disease (IBD) indications following FDA label expansions for genital and scalp psoriasis. RINVOQ sales reached $2.1 billion, up 20.2% operationally, with significant gains in gastroenterology prescriptions for ulcerative colitis. Conversely, HUMIRA global sales declined 40.3% operationally to $688 million, though this remained consistent with expectations given biosimilar competition.
Beyond immunology, neuroscience and other segments demonstrated resilience. Neuroscience revenues nearly hit $2.9 billion, a 24.3% operational increase, driven by double-digit gains in the migraine portfolio (including UBRELVY, QULIPTA, and BOTOX Therapeutic) and growth in VRAYLAR. VYALEV, a Parkinsonโs therapy, is on track to achieve blockbuster status with sales of $201 million. In oncology, total revenues were over $1.6 billion, down 3% operationally, as IMBRUVICA sales fell 24.7% due to IRA pricing and competition, though VENCLEXTA grew 9.7%. The aesthetics business reached nearly $1.2 billion in global sales; while BOTOX Cosmetic rose 17%, JUVรDERM sales decreased 2.9% amid lingering inflationary dynamics in dermal filler markets.
Looking ahead to the second quarter, AbbVie anticipates net revenues of approximately $16.7 billion with adjusted EPS between $3.74 and $3.78, excluding potential acquired IPR&D expenses beyond the first quarter. The company also highlighted significant pipeline progress, including positive Phase III data for SKYRIZI in Crohnโs disease (the AFFIRM study met endpoints), which supports a U.S. submission already under review, and obesity candidate ABBV-295 showing nearly 10% weight loss at 12 weeks. Regulatory submissions for Etentamig are now expected by the end of 2026, reinforcing AbbVieโs long-term growth strategy through business development and innovation.
๐ AbbVie Q1 adjusted EPS $2.65 and revenue $15B, both exceeding analyst expectations.
๐งฌ Immunology leaders SKYRIZI and RINVOQ drove growth with double-digit gains across portfolios.
โ HUMIRA global sales fell 40.3% operationally due to biosimilar competition.
๐ AbbVie reported Q1 adjusted EPS of $2.65 and revenue of $15.0 billion, exceeding analyst expectations.
๐ฐ Full-year adjusted EPS guidance was raised to $14.08โ$14.28 with 2026 net revenue expected at approximately $67.3 billion.
๐งฌ Immunology portfolio showed strong momentum, with SKYRIZI generating $4.5B (+29%) and RINVOQ generating $2.1B (+20%).
๐ง Neuroscience products including VRAYLAR, the migraine portfolio, and VYALEV all posted double-digit growth gains.
๐ Phase III data for SKYRIZI in Crohnโs was positive, and an obesity candidate (ABBVโ295) showed nearly 10% weight loss at 12 weeks.
โ๏ธ AbbVie raised expectations for global SKYRIZI revenue to $21.6B and RINVOQ sales to $10.2B based on expanded indications.
๐ง Neuroscience total revenues were revised up to $12.6 billion, driven by momentum across the portfolio.
๐ Oncology revenues totaled over $1.6 billion, slightly down 3% operationally, with VENCLEXTA sales increasing 9.7%.
๐งด Aesthetics business revenue rose 5.1% to nearly $1.2 billion, led by a 17% increase in BOTOX Cosmetic sales.
โ ๏ธ HUMIRA global sales declined 40.3% operationally due to biosimilar competition but remained within management expectations.
๐ R&D expenses included a $0.41 unfavorable impact from acquired in-process R&D, though adjusted gross margins remained at 83.6%.
โ CEO Rob Michael described the quarter as an "excellent start" with performance exceeding expectations across the diverse portfolio.
๐ฌ Chief Scientific Officer Roopal Thakkar highlighted positive AFFIRM study data for SKYRIZI in Crohnโs disease induction.
Bullish Signals
AbbVie Q1 adjusted EPS hit $2.65, beating guidance by $0.07.
Net revenues reached $15B, surpassing estimates and growing 12.4%.
Full-year adjusted EPS guidance raised to $14.08โ$14.28.
CEO Rob Michael says the company started the year excellently.
Immunology segment grew strongly with SKYRIZI sales at $4.5B.
SKYRIZI expects global revenues of $21.6B amid demand growth.
FDA approved adding genital and scalp psoriasis results to SKYRIZI label.
RINVOQ global sales reached $2.1B, up 20.2% operationally.
Neuroscience segment revenue rose to nearly $2.9B, up 24.3%.
AbbVie raised full-year neuroscience revenue expectations to $12.6B.
RINVOQ sales expectations raised to $10.2B globally.
Parkinson's therapy VYALEV projected blockbuster sales of $201M.
Oncology revenues resilient with VENCLEXTA sales at $770M.
AbbVie expects total net revenues of $67.3B for 2026.
Aesthetics business posted global sales of nearly $1.2B.
Risk Factors
HUMIRA sales down 40.3% from biosimilar competition.
Tavapadon approval delayed until late 2026, not immediate.
SKYRIZI Crohn's study only met partial endpoints.
Bullish Signals
AbbVie reported Q1 adjusted EPS of $2.65, which exceeded expectations by $0.07 above the midpoint of guidance.
Total net revenues reached $15.0 billion, beating analyst estimates by $300 million and reflecting sales growth of 12.4%.
Management raised full-year adjusted EPS guidance to a range of $14.08โ$14.28, up $0.12 from the previous estimate.
CEO Rob Michael stated the company is 'off to an excellent start to the year' with performance exceeding expectations across its diverse portfolio.
Immunology segment drove strong growth with SKYRIZI reaching $4.5 billion in sales, up 29% operationally and gaining share in psoriatic and IBD indications.
SKYRIZI now expects global revenues of $21.6 billion, an increase of $100 million driven by demand growth in psoriatic and inflammatory bowel disease (IBD).
The FDA approved adding new results to the SKYRIZI label for genital and scalp psoriasis following data presented at the American Academy of Dermatology meeting.
RINVOQ global sales reached $2.1 billion, up 20.2% operationally, with a noted inflection in gastroenterology prescriptions for ulcerative colitis.
Neuroscience segment generated nearly $2.9 billion in revenue, up 24.3% operationally, with migraine portfolio growth driving the increase.
AbbVie raised expectations for total neuroscience revenues to $12.6 billion for the full year, an increase of $100 million.
RINVOQ sales expectations were raised to $10.2 billion globally, reflecting strong performance in rheumatology and gastroenterology.
Parkinson's therapy VYALEV is on track to become a blockbuster with sales of $201 million, up about 10% sequentially.
Oncology revenues showed resilience with VENCLEXTA sales reaching $770 million, up 9.7% operationally supported by emerging combination use.
AbbVie expects total net revenues of approximately $67.3 billion for 2026, an increase of $300 million from previous guidance.
The aesthetics business posted global sales of nearly $1.2 billion, up 5.1% operationally, with BOTOX Cosmetic revenue rising 17% to $668 million.
Risk Factors
AbbVie's HUMIRA global sales declined 40.3% operationally due to biosimilar competition, marking a significant revenue headwind despite expectations of being in line.
IMBRUVICA oncology product saw revenue decline 24.7% operationally due to IRA pricing reductions and competitive pressure in the market.
JUVรDERM sales fell 2.9% amid continued headwinds in key dermal filler markets, attributed to lingering inflationary dynamics rather than a recession.
First-quarter adjusted EPS included a $0.41 unfavorable impact from acquired in-process R&D (IPR&D) expense, reducing reported profitability.
The full-year guidance does not include any estimate for acquired IPR&D expense that may occur beyond the first quarter, creating uncertainty about future quarterly results.
Neuroscience revenues expectations face potential risk as tavapadon faces a delayed timeline with a potential U.S. approval expected later in 2026 instead of immediate launch.
SKYRIZI phase III AFFIRM study data for Crohn's disease subcutaneous induction only met endpoints, requiring ongoing clinical validation to support expanded indications.
AbbVie (ABBV) shares rose approximately 2% in premarket trading on Thursday following a positive earnings report, as the pharmaceutical company raised its full-year earnings outlook after beating first-quarter revenue expectations. The strong Q1 results reinforce the company's position among leading biotechnology stocks according to Seeking Alpha rankings, with analysts noting that AbbVie now presents the most compelling fundamental case due to its robust revenue, increased earnings guidance, scale, and diversification compared to peer Buy-rated companies. This financial performance has been viewed as significant for investors considering the healthcare sector, particularly given the company's ability to generate consistent growth despite market fluctuations.
Seeking Alpha's Quant Ratings evaluation highlights that the top U.S. biotechnology stocks are assessed based on valuation, growth potential, momentum, and profitability metrics to produce scores ranging from one to five. While other notable names like Moderna (MRNA), Exelixis (EXEL), and Kymera Therapeutics (KYMR) feature in broader sector discussions, AbbVie's specific recent actionsโincluding raising its full-year outlookโhave strengthened its buy-side appeal for investors focused on pharmaceutical equities. The article notes that such financial beats typically drive upward price momentum, which is particularly relevant for State Street Health Care Select Sector SPDR ETF (XLV) and similar healthcare-focused investment vehicles.
The broader context of the report underscores AbbVie's status near the top of biotech rankings, with specific focus on how its diversified portfolio and strong fundamentals support continued upside potential. The analysis suggests that beyond immediate earnings performance, structural advantages such as scale and diversified revenue streams position AbbVie favorably against competitors in the biotechnology space. Seeking Alpha emphasizes that these factors combined make ABBV an attractive option for investors seeking exposure to healthcare stocks with strong quant metrics and proven ability to exceed market expectations on a consistent basis.
๐ AbbVie shares up ~2% premarket after positive Q1 results.
๐ Quant Rating ranks AbbVie near top of biotech stocks.
๐ Strong fundamentals and scale drive stable investment thesis.
โ Analysts highlight upside potential for large-cap pharma leader.
๐ AbbVie (ABBV) shares rose approximately 2% in premarket trading following positive first-quarter results.
๐ฐ The pharmaceutical giant exceeded revenue expectations for the first quarter, driving a strong financial performance.
๐ Management raised its full-year earnings outlook based on the robust Q1 beat and improved market conditions.
๐ Seeking Alpha ranks AbbVie near the top of biotech stocks based on its Quant Rating system.
๐ The company demonstrates strength through scale, diversification, and solid fundamentals compared to peers.
๐ง Quant Ratings evaluate ABBV's value using metrics like valuation, growth, momentum, and profitability.
๐ Analysts view AbbVie as presenting a compelling fundamental case among top-rated biotech companies.
๐ The investment thesis highlights ABBV's position as a stable large-cap pharma stock with upside potential.
Bullish Signals
AbbVie raised full-year earnings outlook after strong Q1 revenue beat.
Shares up ~2% premarket, showing market confidence in performance.
Company ranks near top of biotech by scale and fundamentals.
Seeking Alpha Quant Ratings confirm compelling buy-case among peers.
Risk Factors
No negative points mentioned.
No downsides or risks included.
Bullish Signals
AbbVie raised its full-year earnings outlook following a strong first-quarter revenue beat, signaling robust financial momentum.
Shares climbed roughly 2% in premarket trading after the positive Q1 results, demonstrating immediate market confidence in the company's performance.
The company sits near the top of biotech rankings based on its scale, diversification, and robust fundamentals compared to peers.
Seeking Alpha's Quant Ratings confirm AbbVie presents a compelling fundamental case among top Buy-rated biotech stocks.
Risk Factors
The article is overwhelmingly positive, highlighting a Q1 revenue beat and raised full-year earnings outlook, leaving no explicit negative points or risks mentioned in the provided text.
No specific concerns such as competitive threats, regulatory issues, declining metrics, or downside catalysts were included in this news summary.
AbbVie (ABBV) shares rallied in premarket trading after the company reported a strong first-quarter beat, exceeding analyst expectations for both earnings per share and revenue. First-quarter adjusted EPS came in at $2.65 per share against a consensus of $2.59, while total revenue reached $15 billion, marking a 12% year-over-year increase above the estimated $14.72 billion. This positive momentum allowed the stock to climb 2.5%, helping it recover some ground following a 13% decline for the year-to-date period as of Tuesday's close.
The financial outperformance was driven significantly by growth in specific business segments, with the immunology division expanding by 16% and the neuroscience division surging 26%. Within immunology, Skyrizi and Rinvoq acted as primary growth drivers, posting 31% and 23% revenue increases respectively. These robust performances from these newer drugs helped more than offset a steep 39% revenue drop associated with Humira, the company's former blockbuster medication that is facing increased competition from biosimilar alternatives.
Looking ahead, AbbVie increased its full-year 2026 adjusted EPS forecast to a range of $14.08โ$14.28, up from the previous projection of $13.96โ$14.16. This upward revision reflects management's growing confidence in sustained performance from its immunology and neuroscience portfolios, placing the new guidance midpoint modestly above the current Wall Street consensus of $14.12. On a GAAP basis, quarterly net income totaled $695 million, or $0.39 per diluted share, which was lower than the year-ago quarter due to non-operating expenses included in the calculation, though adjusted metrics tell a different story of improvement with two consecutive quarters of year-over-year growth.
๐ AbbVie beat estimates with Q1 adjusted EPS of $2.65 and $15B revenue.
๐ Skyrizi and Rinvoq drove growth despite a 39% Humira decline.
๐ Immunology rose 16%, neuroscience surged 26%, and full-year forecast was upgraded.
๐ Stock remains down 13% YTD but adjusted earnings improved for two quarters.
๐ AbbVie reported first-quarter adjusted earnings of $2.65 per share, beating analyst estimates of $2.59.
๐ฐ Total quarterly revenue reached $15 billion, representing a 12% year-over-year increase.
๐ The immunology division grew by 16%, while the neuroscience segment surged by 26%.
๐ Skyrizi and Rinvoq drove growth with revenue increases of 31% and 23% respectively.
โ ๏ธ Strong performance from new products offset a 39% revenue decline in Humira due to biosimilar competition.
๐ ABBV shares rose 2.5% in premarket trading following the positive earnings announcement.
๐ญ The company raised its full-year 2026 adjusted EPS forecast to $14.08โ$14.28.
๐ค Upgraded guidance reflects management confidence in the immunology and neuroscience portfolios.
โ๏ธ GAAP net income declined year-over-year to $0.39 per share due to excluded expenses not captured in adjusted metrics.
๐ Despite the stock recovering some losses, it still faces a 13% year-to-date decline.
๐ง Neuroscience is establishing itself as an increasingly important revenue source for the company.
๐ Adjusted earnings of $2.65 mark the second consecutive quarter of year-over-year improvement.
Bullish Signals
Adjusted EPS reached $2.65, surpassing the $2.59 consensus.
Revenue hit $15 billion, a strong 12% year-over-year increase.
Immunology segment grew 16%, driven by Skyrizi and Rinvoq gains.
AbbVie reported first-quarter adjusted earnings of $2.65 per share, surpassing the analyst consensus estimate of $2.59 and climbing from $2.46 in the same period last year.
Quarterly revenue reached $15 billion, representing a strong 12% year-over-year increase that beat the $14.72 billion analyst projection.
The immunology division grew by 16%, driven by Skyrizi's 31% revenue increase and Rinvoq's 23% growth, successfully offsetting the decline in the Humira franchise.
The neuroscience segment delivered an impressive 26% quarterly surge, demonstrating successful diversification beyond the immunology business.
Management raised its full-year 2026 adjusted EPS forecast to a range of $14.08โ$14.28, upgrading from the previous $13.96โ$14.16 range and placing the midpoint above Wall Street consensus.
Shares of ABBV gained 2.5% in premarket trading to reach $202.63 as investors responded favorably to the earnings beat and upgraded guidance.
AbbVie has achieved two consecutive quarters of year-over-year adjusted earnings improvement, with Q1 results decisively beating the prior-year figure.
Risk Factors
Despite strong earnings, AbbVie shares are still down 13% year-to-date as of Tuesday's market close, indicating significant recent investor skepticism or broader market headwinds.
The company faces a severe structural risk from Humira, which saw a steep 39% revenue drop as it loses market share to competitive biosimilar alternatives.
On a GAAP basis, quarterly net income totaled only $695 million ($0.39 per diluted share), representing a significant year-over-year decline compared to the prior year's $1.29 billion.
Full-year 2026 adjusted EPS guidance of $14.08โ$14.28 places the company right at or near Wall Street consensus estimates, leaving little room for error given the high valuation implied by recent premarket gains.
The stock needs to make up considerable lost ground from its 13% year-to-date decline before any short-term momentum translates into sustained value.
Pfizer and AbbVie stand as two of the leading U.S. drugmakers with diverse therapeutic portfolios, yet their current trajectories offer distinct investment narratives. Pfizer derives roughly 27% of its revenues from oncology, a segment strengthened by the 2023 acquisition of Seagen, which drove an 8% increase in oncology revenues during 2025 through drugs like Xtandi and Padcev. The company has successfully reduced its reliance on COVID business, with non-COVID operational revenues up 14% year over year in 2025 driven by products such as Vyndaqel and Eliquis. Pfizer also plans to initiate 20 pivotal studies in 2026, including 10 for obesity candidates acquired from Metsera and four for the dual PD-1/VEGF inhibitor PF-08634404 from 3SBio, expecting continued double-digit growth from recent acquisitions. Additionally, Pfizer maintains a dividend yield of approximately 6.3% and has invested around $9 billion in M&A deals in 2025, though it faces headwinds including upcoming patent expirations for key products like Eliquis and Xtandi between 2026 and 2030.
In contrast, AbbVie has effectively offset the expiration of its blockbuster Humira, which once contributed over 50% of total revenues, through the success of its immunology therapies Skyrizi and Rinvoq. These newer drugs generated combined sales of $26.0 billion in 2025 with year-over-year growth exceeding 40%, projecting sales above $31 billion for 2026. Immunology now accounts for about half of AbbVie's total revenues, while its neuroscience portfolio grew nearly 20% to $10.8 billion in 2025 driven by Botox Therapeutic and migraine drugs Ubrelvy and Qulipta. The company also invested more than $5 billion in M&A deals in 2025, focusing on early-stage pipelines in immunology, oncology, and neuroscience, although it faces challenges such as Humira's biosimilar erosion and a 5.9% decline in aesthetics portfolio sales during the same period.
Analyst estimates paint a divergent picture for the two companies regarding 2026 financial performance. The Zacks Consensus Estimate projects Pfizer's 2026 sales to decline by approximately 2.5% and earnings per share (EPS) to fall by 7.5%, with EPS rising slightly from $2.97 to $2.98 in 2026 before stabilizing at $2.82 for 2027. Conversely, AbbVie is expected to see sales growth of 9.6% and a substantial 45.3% increase in EPS for 2026, with estimates rising from $14.46 to $14.53 per share. Stock performance over the past year reflects this dynamic, with Pfizer shares up 24.2% compared to AbbVie's 21.3%, while the broader industry returned 25.8%. Valuation metrics also differ, with Pfizer trading at a forward price/earnings ratio of 9.29 compared to AbbVie's 14.14, though AbbVie currently trades above its five-year mean P/E of 13.81.
๐ AbbVie replaced Humira revenue with Skyrizi/Rinvoq generating $26B in 2025.
๐ Pfizer oncology revenues rose 8% following Seagen acquisition despite flat COVID outlook.
โ Both companies face patent cliffs and pipeline headwinds ahead of 2026.
๐ฐ AbbVie offers strong earnings growth potential with 45.3% estimated increase for 2026.
๐ Pfizer trade at lower P/E ratio but faces declining sales expectations in 2026.
๐ฅ AbbVie and Pfizer are two leading U.S. drugmakers with diverse portfolios across oncology, immunology, neuroscience, and vaccines.
๐ AbbVie offset Humira's loss of exclusivity with newer immunology therapies Skyrizi and Rinvoq, which now generate about half of its revenue.
๐ฌ Both companies have robust R&D pipelines intended to drive innovation and long-term growth in their respective sectors.
๐งฌ Pfizer strengthened its oncology position with the 2023 Seagen acquisition, contributing to an 8% revenue increase in 2025.
๐ Pfizer's non-COVID revenues are improving driven by products like Vyndaqel, Padcev, and Eliquis, with recently acquired products rising 14% in 2025.
๐ค Pfizer invested approximately $9 billion in M&A deals in 2025 to rebuild its pipeline, including acquisitions of Metsera and licensing from 3SBio.
๐งช Pfizer plans 20 pivotal studies in 2026, including ten for obesity candidates from the Metsera acquisition.
โ ๏ธ Pfizer's 2026 outlook shows mostly flat to slightly negative growth due to declining COVID sales, Medicare Part D impacts, and upcoming patent expirations.
๐ The Zacks Consensus Estimate for Pfizer's 2026 implies a year-over-year decrease of 2.5% in sales and 7.5% in earnings.
๐ฐ Pfizer offers an impressive dividend yield of around 6.3% alongside significant cost reduction efforts to improve R&D productivity.
๐ AbbVie's Skyrizi and Rinvoq combined sales reached $26 billion in 2025, growing over 40%, with expectations for more than $31 billion in 2026.
๐ง AbbVie's neuroscience portfolio saw a 20% sales increase to $10.8 billion in 2025, driven by Botox Therapeutic and migraine drugs Ubrelvy and Qulipta.
๐ฌ AbbVie invested over $5 billion in 2025 for M&A deals to bolster its pipeline in immunology, oncology, and neuroscience.
โ ๏ธ AbbVie faces near-term headwinds including Humira biosimilar erosion, slowing oncology sales, and a 5.9% decline in aesthetics portfolio sales.
๐ The Zacks Consensus Estimate for AbbVie's 2026 implies a 9.6% sales increase and 45.3% earnings growth compared to the previous year.
๐ Pfizer stock has risen 24.2% over the past year, while AbbVie jumped 21.3%, outperforming or matching industry returns of 25.8%.
๐ AbbVie trades at a lower forward P/E ratio of 14.14 compared to Pfizer's 9.29 and the industry average of 17.42.
Bullish Signals
AbbVie immunology therapies grew sales $26B in 2025 with over 40% YoY growth.
Skyrizi and Rinvoq sales expected to exceed $31B in 2026.
Neuroscience portfolio sales rose 20% to $10.8B in 2025 driven by key drugs.
Pfizer dividend yield reaches 6.3% with oncology revenue growth of 8% in 2025.
Pfizer invested $9B in M&A deals including Metsera acquisition for pipeline depth.
AbbVie invested over $5B in 2025 to acquire innovative pipeline candidates.
Zacks Consensus predicts AbbVie 2026 earnings increase of 45.3%.
Pfizer expects double-digit growth in 2026 with 10 pivotal obesity studies planned.
Risk Factors
Pfizer guidance shows flat to negative growth for 2026.
Pfizer sales decline due to COVID drugs, Medicare Part D, and patent expirations until 2030.
AbbVie faces biosimilar erosion, oncology slowdown, and a 5.9% aesthetics sales drop in 2025.
AbbVie consensus earnings estimate fell from $16.15 to $16.14 per share over 60 days.
AbbVie shares trade above five-year mean of 13.81, signaling valuation concerns.
Bullish Signals
AbbVie successfully offset the impact of Humira's loss of exclusivity with its newer immunology therapies Skyrizi and Rinvoq, which generated combined sales of $26.0 billion in 2025 representing year-over-year growth of more than 40%.
In 2026, AbbVie expects combined Skyrizi and Rinvoq sales to exceed $31 billion, signaling strong top-line growth prospects for its core immunology business.
AbbVie's neuroscience portfolio contributed significantly to top-line growth with sales increasing almost 20% to $10.8 billion in 2025 driven by Botox Therapeutic, Vraylar, and newer migraine drugs Ubrelvy and Qulipta.
Pfizer achieved an impressive dividend yield of around 6.3%, providing attractive income potential for investors while maintaining strong positions in oncology with its acquired products driving 8% revenue growth in 2025.
Pfizer invested around $9 billion in M&A deals in 2025 including the acquisition of Metsera and licensing from 3SBio, which adds ultra-long-acting obesity candidates and pipeline depth for future innovation.
AbbVie invested more than $5 billion in 2025 to acquire innovative pipeline candidates, demonstrating a strong commitment to bolstering its early-stage pipeline for long-term growth.
The Zacks Consensus Estimate for AbbVie's 2026 earnings shows a year-over-year increase of 45.3%, reflecting robust market expectations despite some near-term headwinds.
Pfizer expects its recently launched and acquired products to record continued double-digit growth in 2026, including specific plans to start 20 pivotal studies that include 10 for obesity candidates from the Metsera acquisition.
Risk Factors
Pfizer's 2026 revenue and earnings guidance failed to impress investors, representing mostly flat to slightly negative growth.
Pfizer faces declining sales of its COVID products, unfavorable impact from Medicare Part D redesign, and upcoming patent expirations for key products like Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi in the 2026-2030 period.
AbbVie faces near-term headwinds including Humira's biosimilar erosion, a slight slowdown in oncology sales, and declining sales of its Aesthetics unit due to macro challenges with a 5.9% decline in global sales in 2025.
The Zacks Consensus Estimate for AbbVie's 2027 earnings has decreased from $16.15 to $16.14 per share over the past 60 days, indicating weakening market expectations.
AbbVie's shares currently trade higher than its five-year mean of 13.81, suggesting potential valuation concerns despite trading at 14.14 forward earnings.
The dividend roundup published on April 10, 2026, by Seeking Alpha highlights recent payout activities and declarations from several major companies, including AGNC Investment Corp., Abbott Labs, and AbbVie. According to the article, Agree Realty Corporation (ADC) announced an increase in its dividend payout, reflecting a trend of enhanced returns to shareholders within the real estate sector. Alongside this, AGNC Investment Corp. (AGNC) and Healthpeak Properties, Inc. (DOC) have declared their respective dividends for the period, maintaining their positions as preferred income stocks for investors seeking regular cash flow.
Looking beyond the immediate announcements, the article also anticipates significant dividend declarations scheduled for next week from AbbVie Inc. (ABBV) and Abbott Laboratories (ABT). These two pharmaceutical and healthcare giants are frequently monitored by investors for their consistency in rewarding shareholders with quarterly distributions. The news piece contextualizes these corporate actions within a broader market landscape that includes major dividend-focused exchange-traded funds (ETFs) such as the iShares Select Dividend ETF (DVY), Vanguard High Dividend Yield Index Fund ETF (VYM), and the Vanguard Dividend Appreciation Index Fund ETF (VIG), which often hold these companies in their portfolios.
The summary notes that this roundup serves as a comprehensive update for investors tracking income-generating assets across various sectors, from real estate investment trusts like Agree Realty to healthcare leaders like AbbVie. While specific payout amounts and record dates are not detailed in the text, the focus remains on the declarations of dividends by AGNC, Healthpeak Properties, Agree Realty's hike, and the forthcoming actions by Abbott Labs and AbbVie. Seeking Alpha frames these developments as key events for investors evaluating their dividend portfolios during this week.
๐ Published April 10, 2026, this dividend roundup by Seeking Alpha highlights key payouts.
๐ Agree Realty increases dividend payout for the current week's coverage period.
๐ฅ AGNC, Healthpeak, and major players like AbbVie announce upcoming dividend declarations.
๐ฆ Related ETFs DVY and VYM tracked alongside these income-generating stock activities.
๐ This dividend roundup article was published on April 10, 2026, by Seeking Alpha News Editor Sinchita Mitra.
๐ข It highlights recent dividend activities from several companies including AGNC Investments, Healthpeak Properties, and Agree Realty Corporation.
๐ Agree Realty (ADC) announced an increase in its dividend payout for this week's coverage.
๐ฅ AGNC Investment Corp. (AGNC) declared a dividend to its shareholders.
๐ฅ Healthpeak Properties, Inc. (DOC) also declared dividends during this reporting period.
๐ The article mentions upcoming dividend declarations from major players like AbbVie (ABBV) and Abbott Labs (ABT).
๐ The update provides a summary of current market activity for investors focused on income-generating stocks.
๐ฆ Several ETFs are listed as related entities, including the iShares Select Dividend ETF (DVY) and Vanguard High Dividend Yield Index Fund (VYM).
Bullish Signals
AbbVie (ABBV) to declare dividends next week, committing to shareholder returns.
AGNC Investment Corp. declared dividend payment, maintaining status as attractive income stock.
Risk Factors
No negative aspects or risks identified.
No declining metrics, regulatory concerns, or threats.
Neutral article lacks bearish financial data.
Bullish Signals
AbbVie (ABBV) is expected to declare dividends next week, signaling continued commitment to shareholder returns.
Agree Realty (ADC) announced an increase in its dividend payouts, reflecting strong cash flow generation and confidence in future earnings.
AGNC Investment Corp. (AGNC) declared a new dividend payment, maintaining its status as an attractive income stock for investors seeking reliable yields.
Risk Factors
The article contains no negative aspects or risks related to AbbVie (ABBV).
There is no mention of declining metrics, regulatory concerns, competitive threats, or downside catalysts for AbbVie.
The provided text is a neutral dividend roundup and lacks specific financial data that could be interpreted as bearish.
AbbVie Inc. (ABBV) is currently positioned for a recovery in both profits and dividends, according to an analysis from Envision Research Investing Group Leader Lucas Ma published on April 9, 2026. Upcoming first-quarter 2026 earnings are anticipated to demonstrate robust growth, with estimated earnings per share (EPS) of $2.93, representing a 19.1% year-over-year increase, and revenue projected at $14.72 billion, an 10.3% rise compared to the prior year. This performance aligns with the article's characterization of the stock as fairly valued and well-positioned for growth recovery. The analysis also notes that dividend growth appears to be stabilizing, marked by a recent annual increase of 5.48%, which signals a potential reversal in the deceleration trend observed previously.
From a product pipeline perspective, AbbVie's key assets Skyrizi and Rinvoq are successfully offsetting the decline associated with its former flagship drug, Humira. However, the article highlights significant competitive threats that investors should monitor closely, specifically emerging from competitor Johnson & Johnson (JNJ). JNJ is expected to launch its own competing therapies, Tremfya and Icotyde, which may impact AbbVie's market dynamics in the medium to long term. These developments underscore the strategic pressure on AbbVie while it navigates a transitional period of drug patent expirations and competitive innovation.
The report was issued by Lucas Ma, who leads Envision Early Retirement and brings over 20 years of investment experience along with a Master's degree in Quantitative Investment and a PhD in Mechanical Engineering from Stanford University. Ma emphasizes the publication's core style of providing actionable and unambiguous ideas based on independent research, aiming to help members achieve returns that outperform the S&P 500 while avoiding heavy drawdowns during market volatility. The author holds a beneficial long position in JNJ shares and clarifies that he is not receiving compensation other than from Seeking Alpha for this specific article. Seeking Alpha's standard disclosures state that past performance does not guarantee future results, no specific investment advice is being given, and the views expressed are those of the third-party author rather than the platform itself.
๐ AbbVie earnings projected to grow 19.1% YoY with EPS of $2.93 in Q1 2026.
๐ฐ Revenue expected to reach $14.72B, marking a 10.3% year-over-year increase for the quarter.
๐ Skyrizi and Rinvoq driving recovery as Humira decline is offset by new products.
โ Competition from J&J's Tremfya poses key risk to monitor closely ahead of April 29 earnings.
๐ AbbVie (ABBV) is positioned for a growth recovery in both profits and dividends according to the latest investment analysis.
๐ฐ Upcoming First Quarter 2026 earnings are projected to show EPS of $2.93, representing a 19.1% year-over-year increase.
๐ Revenue for the quarter is expected to reach $14.72 billion, marking a 10.3% growth compared to the previous year.
๐ต Dividend growth is stabilizing with the most recent annual increase recorded at 5.48%.
๐ The portfolio's revenue recovery is being driven by Skyrizi and Rinvoq offsetting the decline from Humira.
โ ๏ธ Competitive threats from Johnson & Johnson's Tremfya and Icotyde are noted as key risks to monitor closely.
๐ FQ1 earnings results are expected to be released on April 29, 2026.
๐ The analysis emphasizes the need to watch for potential deceleration in growth after recent increases.
Bullish Signals
FQ1 2026 EPS up 19.1% to $2.93, revenue rising 10.3% to $14.72B.
Dividend increased 5.48%, signaling stabilization after deceleration.
Skyrizi and Rinvoq offsetting Humira decline for stability.
Earnings expected April 29, supporting profit recovery.
Stock fairly valued with strong growth trajectory.
Analyst holds JNJ shares, creating a conflict of interest in assessing competitor risks.
Bullish Signals
Upcoming FQ1 2026 earnings are expected to show robust growth, with EPS of $2.93 representing a 19.1% year-over-year increase and revenue of $14.72B up 10.3%.
Dividend growth appears to be recovering with the latest annual increase at 5.48%, signaling potential stabilization after recent deceleration.
Skyrizi and Rinvoq are effectively offsetting Humira's decline, providing a solid foundation for continued revenue stability.
AbbVie is positioned for a profit recovery with earnings expected on April 29.
The stock is described as fairly valued and well-positioned for future growth trajectories.
Risk Factors
Skyrizi and Rinvoq are only partially offsetting the significant decline in revenue from Humira, indicating lingering dependency on expiring patents.
Competitive threats from Johnson & Johnson's Tremfya and Icotyde warrant close monitoring as they could erode future market share for AbbVie's core biologics portfolio.
The article notes recent deceleration in dividend growth despite the latest annual increase, suggesting volatility in shareholder returns.
Analyst disclosure reveals a beneficial long position in shares of JNJ, which may create a potential conflict of interest regarding the assessment of competitive threats from Tremfya and Icotyde.
AbbVie Inc. (ABBV) remains well-positioned for long-term growth despite recent share price consolidation and near-term geopolitical headwinds, according to an analysis published on March 27, 2026. The core expectation is that the biopharmaceutical company's key assets, Skyrizi and Rinvoq, will drive double-digit revenue growth in 2026 and continue to exceed the company's initial guidance as Humira erosion moves into the rearview mirror.
The analysis anticipates accelerating dividend increases and heightened business development activity as previous acquisitions are fully digested by the organization. However, the author notes that AbbVie's obesity pipeline currently lacks sufficient breadth and differentiation. To enhance competitiveness in this area, a timely acquisition of assets to combine with the existing ABBV-295 initiative is deemed critical.
Since an October 2025 update outlining strong commercial progress, shares of AbbVie have declined approximately 10%, prompting the reassessment of its market positioning and emerging efforts in the obesity sector. The author, who leads the investing group Growth Stock Forum, emphasizes that this perspective should not be regarded as a buy or sell recommendation or investment advice, noting that past performance is no guarantee of future results and seeking alpha's disclosures regarding third-party analysis and potential lack of licensing for its authors.
๐ Stock consolidated after strong Q4 2025 progress despite a recent 10% decline.
๐ Skyrizi and Rinvoq projected to drive double-digit revenue growth in 2026.
๐ฐ Dividend increases anticipated as Humira erosion issues are resolved.
โ Obesity pipeline lacks breadth; new assets or internal combination required for competitiveness.
๐ Independent author cites strong historical returns without declared conflicts of interest.
๐ Published on March 27, 2026, the article analyzes AbbVie's stock performance despite a recent 10% decline since October 2025.
๐ Skyrizi and Rinvoq are projected to drive double-digit revenue growth in 2026, exceeding initial company guidance.
๐ฐ With Humira erosion largely resolved, the author anticipates accelerated dividend increases in the near term.
๐ค Management is expected to pursue increased business development activity as earlier acquisitions are fully digested.
โ ๏ธ The obesity pipeline is noted to lack breadth and differentiation without timely acquisition of new assets.
๐งฌ Combining existing AbbVie-295 with acquired assets is critical for enhancing competitiveness in the obesity market.
๐ AbbVie shares have consolidated following a strong commercial progress update from October 2025.
๐ข The article was written by an independent investor who leads the Growth Stock Forum without compensation.
โ๏ธ No conflicts of interest were declared, with no stock positions held in the mentioned companies at the time of writing.
๐ Historical portfolio performance cited includes a 137.6% increase for biotech Top Picks and a 23.2% CAGR for the core portfolio.
Bullish Signals
ABBV positioned for long-term growth despite market consolidation.
Skyrizi and Rinvoq drive double-digit 2026 revenue growth.
Asset acquisition critical to mitigate thin pipeline risks.
Bullish Signals
AbbVie Inc. (ABBV) is well-positioned for long-term growth despite recent market consolidation.
Skyrizi and Rinvoq are expected to drive double-digit revenue growth in 2026, exceeding the company's initial guidance.
With Humira erosion largely behind the company, accelerating dividend increases are anticipated.
Increased business development activity is expected as previous acquisitions continue to be successfully digested.
Risk Factors
Shares of AbbVie Inc. (ABBV) are down approximately 10% since the author's October 2025 update, indicating recent market weakness despite the bullish outlook.
The company faces near-term geopolitical headwinds that could impact operational stability and revenue realization in the upcoming fiscal year.
AbbVieโs obesity pipeline lacks breadth and differentiation, creating a significant competitive vulnerability as the company seeks to enhance competitiveness with ABBV-295.
Timely acquisition of assets is critical to mitigate risks related to the limited pipeline depth in the obesity market segment.
Piper Sandler maintained its Buy rating on AbbVie (ABBV) in a report released on March 27, with analyst David Amsellem setting a price target of $299.00. Amsellem focuses on the Healthcare sector and has a history of recommendations covering stocks such as Amgen and Biogen; TipRanks data indicates his average return is 6.5% with a 50.90% success rate. While AbbVie also received a Buy rating from TipRanks โ Googleโs Google Drug Manufacturers โ General in a report issued the previous day, it was simultaneously reiterated that the company holds a Hold rating from TipRanks โ Anthropic on the same date.
The analysis of AbbVie is supported by its financial performance for the quarter ending December 31, during which the company reported quarterly revenue of $16.62 billion and a net profit of $1.82 billion. This represents a significant improvement over the prior year, when AbbVie earned revenue of $15.1 billion and recorded a GAAP net loss of $22 million. Despite these positive earnings metrics, broader market sentiment appears cautious due to corporate insider activity, which has been rated negative for the stock over the past quarter due to increased insider selling relative to earlier this year.
Specific insider transactions highlight this sentiment; for instance, David Ryan Purdue, SVP and Controller of AbbVie, sold 5,230 shares totaling $1,221,518.80 earlier in the month, marking a notable increase in sell activity among the company's 41 tracked insiders. While Piper Sandler remains bullish, TipRanks aggregates show conflicting analyst opinions on the stock from different firms covering the Drug Manufacturers sector, alongside related headlines noting insider selling spooking investors and AbbVie entering agreements for developing an antibody platform and launching new product indices in aesthetics.
๐ Piper Sandler analyst reiterated a "Buy" rating with a $299 price target.
๐ฐ Quarterly revenue hit $16.62B and net profit reached $1.82B.
โ๏ธ Insider sentiment remains negative following significant share sales by executives.
๐ค Analyst David Amsellem boasts a 50.9% historical success rate on picks.
- ๐ Piper Sandler analyst David Amsellem reiterated a "Buy" rating on AbbVie with a price target of $299.00.
- ๐ฐ The company reported quarterly revenue of $16.62 billion and net profit of $1.82 billion for the quarter ending December 31.
- ๐ This represents significant growth from last year, which saw $15.1 billion in revenue and a GAAP net loss of $22 million.
- ๐งโ๐ผ Corporate insider sentiment is currently negative due to increased selling activity among 41 insiders over the past quarter.
- ๐ธ Specifically, SVP David Ryan Purdue sold 5,230 shares worth approximately $1.22 million earlier this month.
- โ๏ธ Other analyst coverage includes a "Buy" from TipRanks and Google's Drug Manufacturers team, though Anthropic maintained a "Hold."
- ๐ค Amsellem covers the Healthcare sector with a historical average return of 6.5% and a 50.90% success rate on recommended stocks.
- โพ AbbVie was recently named the Official Pharmaceutical Partner of Major League Baseball in a separate announcement.
Bullish Signals
Piper Sandler analysts reiterated a 'Buy' rating on AbbVie (ABBV), demonstrating continued institutional confidence in the stock.
David Amsellem of Piper Sandler set a price target of $299.00, providing a clear upside potential for investors following his analysis.
AbbVie reported strong quarterly revenue of $16.62 billion based on the quarter ending December 31, representing growth from the prior year's $15.1 billion.
The company turned its profit situation around significantly, reporting a net profit of $1.82 billion compared to a GAAP net loss of $22 million last year.
Amsellem has a historical track record with an average return of 6.5% and a 50.90% success rate on his recommended stocks.
AbbVie was recognized as the Official Pharmaceutical Partner of Major League Baseball, expanding its brand visibility and partnerships.
Risk Factors
Corporate insider sentiment is negative as over the past quarter, 41 insiders have increased their share sales compared to earlier in the year.
David Ryan Purdue, SVP and Controller of AbbVie (ABBV), recently sold 5,230 shares worth $1.22 million, signaling a lack of confidence from top-level executives.
AbbVie is facing mixed analyst sentiment, with TipRanks noting that while Piper Sandler maintains a Buy rating, Anthropic has reiterated a Hold rating on the stock.
The recent surge in insider selling is explicitly noted as spooking investors, causing the AbbVie stock to slide in price.
According to Simply Wall St, AbbVie (ABBV) is currently trading at approximately US$205 per share, reflecting recent declines of 6.6% over the past week, 8.7% over the past month, and 10.5% year to date. Despite this recent weakness, the stock has generated returns of 5.3% over one year, 44.5% over three years, and 132.7% over five years. The analysis highlights that investor sentiment remains focused on AbbVie's product portfolio and its standing among large US pharmaceutical companies, as well as broader sector flows affecting healthcare valuations.
A Discounted Cash Flow (DCF) model using a two-stage free cash flow to equity approach estimates AbbVie's intrinsic value at US$366.91 per share, based on the latest twelve-month free cash flow of approximately US$18.0 billion and projected figures reaching US$31.5 billion by 2030. This implies the stock is trading about 44.1% below its DCF estimate, signaling it may be undervalued according to this specific metric. The model uses explicit analyst estimates extending through 2030 before extrapolating further into the future to calculate current value.
However, a Price-to-Earnings (P/E) analysis presents a contrasting view, showing AbbVie trading at a P/E ratio of 86.68x compared to a peer average of 22.56x and a biotech industry average of 16.90x. Simply Wall St calculates a fair P/E ratio of 38.23x for AbbVie based on its earnings growth, margins, and risk profile, which suggests the stock is overvalued relative to this metric since its current P/E significantly exceeds the fair estimate. The article concludes by suggesting investors can use "Narratives" on the Simply Wall St platform to reconcile these different valuation views, with community estimates of fair value ranging from US$249 to US$253 based on various forward earnings and multiplier assumptions.
Simply Wall St assigns AbbVie an overall value score of 3 out of 6, indicating it screens as undervalued on half of the six evaluation checks. The platform notes that this analysis is general in nature, relies on historical data and analyst forecasts using an unbiased methodology, and does not constitute financial advice or a recommendation to buy or sell. The company has no position in any stocks mentioned and aims to provide long-term focused analysis driven by fundamental data without factoring in the latest price-sensitive announcements or qualitative material.
๐ Stock dropped 6.6% this week despite strong long-term gains.
๐ฐ DCF model suggests current price is ~44% below intrinsic value.
โ ๏ธ P/E ratio of 86.68x significantly exceeds peer and industry averages.
๐ AbbVie's stock price has recently weakened, declining 6.6% over the past week and 10.5% year-to-date while trading around US$205.20.
๐ Despite recent declines, the stock maintains a long-term track record with 5-year returns of 132.7% and a 44.5% gain over three years.
๐งฌ Investors are closely monitoring AbbVie due to ongoing attention on its product portfolio and competitive position within the large US pharmaceutical sector.
๐ Simply Wall St assigns AbbVie a value score of 3 out of 6, indicating it passes as undervalued on half of their six screening checks.
๐ฐ A Discounted Cash Flow (DCF) model estimates an intrinsic value of US$366.91, suggesting the stock is approximately 44.1% below that DCF estimate.
๐ The DCF analysis specifically uses a Two-Stage Free Cash Flow to Equity approach with explicit analyst forecasts extending out to 2030.
๐น AbbVie currently trades at a P/E ratio of 86.68x, which is significantly higher than the peer average of 22.56x and industry average of 16.90x.
โ ๏ธ Based on a proprietary Fair Ratio of 38.23x, the company's current valuation screens as overvalued compared to its earnings growth profile and risk factors.
๐ Simply Wall St suggests using "Narratives" to build custom fair value stories that align forecasts with specific views on revenue and earnings.
๐ก One community narrative example estimates a fair value near US$253 using a 17.5x forward P/E multiplied by projected 2026 EPS of US$14.47.
๐ Another investor perspective estimates a fair value around US$249 based on a 24.0x P/E applied to 2029 earnings forecasts.
โ ๏ธ The article states that its analysis is general in nature, relies on historical data and analyst forecasts, and does not constitute financial advice.
๐ Simply Wall St explicitly notes that their methodology may not factor in the latest price-sensitive announcements or specific qualitative material.
Bullish Signals
Although recent stock weakness has pushed the share price down, AbbVie still delivers a strong long-term performance with returns of 44.5% over the past three years and 132.7% over five years.
Based on a Discounted Cash Flow model, AbbVie trades at approximately 44.1% below its estimated intrinsic value of US$366.91, signaling significant upside potential.
The company generated robust free cash flow of around US$18.0b in the latest twelve months, with projections reaching US$31.5b by 2030.
Investors can utilize Simply Wall St's automated Narrative tools to track evolving forecasts for revenue, earnings, and fair value against a current market price of around US$205.
Risk Factors
AbbVie's share price has declined significantly, falling 6.6% over the past week, 8.7% over the past month, and 10.5% year to date, resulting in a current price of approximately US$205.
The stock's one-year return of 5.3% is lagging behind its peers, raising concerns about relative performance despite strong historical growth over longer periods.
On a P/E basis, AbbVie trades at a multiple of 86.68x, which sits well above Simply Wall St's Fair Ratio estimate of 38.23x and the industry average of 16.90x, suggesting significant overvaluation.
Simply Wall St's valuation model yields a score of only 3 out of 6, indicating that the company fails to screen as undervalued on the majority of key checks.
The provided text indicates that AbbVie, identified by its New York Stock Exchange ticker ABBV, is involved in an initiative to expand awareness and conduct psychedelic research. However, the specific details regarding this program are obscured because the content of the article appears to be inaccessible behind a login wall or subscription paywall on the Kalkine Media platform. The visible text includes standard website navigation prompts, such as instructions for users to log in, create an account, or submit a form to continue reading the full story.
The surrounding context provided in the snippet suggests this news item is part of a broader healthcare and pharmaceutical sector update published on March 25, 2026, at 01:15 PM PDT. While other headlines are visible alongside the AbbVie entryโmentioning Transocean reaching an annual peak, Gray Media expanding its NYSE presence, AstraZeneca gaining momentum, and Teleflex rallying after an upgradeโthe actual details of AbbVie's specific research activities, financial implications, or strategic motivations for entering psychedelic space are not disclosed in this excerpt.
Furthermore, the remainder of the text is dedicated to legal disclaimers and terms regarding data submission. It confirms that by proceeding on the site, users consent to be contacted by Kalkine Media representatives for marketing purposes, including telemarketing calls or emails from Kalkine group entities. No specific numerical data, dates beyond the publication timestamp, or quotes from company executives are included in this accessible portion of the news feed.
๐ AbbVie expands psychedelic research within the Russell 1000 index.
๐ Healthcare evolves through scientific innovation and therapeutic diversification.
๐ Access full content via free account registration or form submission.
โ Registration confirms consent for marketing communications from Kalkine Media.
๐๏ธ AbbVie (NYSE:ABBV) is expanding its awareness and psychedelic research initiatives within the Russell 1000 index context.
๐ The healthcare sector is evolving through scientific research, public engagement, and therapeutic diversification.
โก A combination of established pharmaceutical capabilities and new research avenues reflects this blend.
๐ Readers must log in, create a free account, or fill out a form to access the full article content.
โ By submitting details, users confirm consent for Kalkine Media representatives to contact them regarding marketing offers and discussions.
๐ Contact methods include email and phone calls made by Kalkine group's telemarketing entities on behalf of the publisher.
Bullish Signals
No meaningful points found.
Input array is empty.
Unable to condense content.
Missing data for processing.
List contains no items.
Bullish Signals
Risk Factors
The provided article is a promotional landing page and not substantive financial news; it contains no actual negative points, risks, or data about AbbVie.
The text lists unrelated positive headlines for competitors like Transocean (NYSE:RIG) and AstraZeneca (NYSE:AZN), but offers no information on AbbVie's specific operational or financial challenges.
The analysis compares Eli Lilly (LLY) and AbbVie (ABBV) as leading U.S. drugmakers with significant market capitalizations, strong R&D pipelines, and presence in key areas like immunology, oncology, and neuroscience. Eli Lilly's growth is heavily driven by its GLP-1 therapies, Mounjaro and Zepbound, which generated combined sales of $36.5 billion in 2025, accounting for approximately 56% of total revenues. The company has secured approvals for multiple new therapies including Omvoh, Jaypirca, Ebglyss, and Kisunla, with expectations that these alongside Mounjaro, Zepbound, Inluriyo, and Orforglipron will drive 2026 sales growth. Lilly is focusing on expanding into oral GLP-1 treatments via orforglipron, anticipated for U.S. launch in the second quarter of 2026, aiming to counter the first-to-market advantage gained by Novo Nordisk with its oral Wegovy pill approved in December 2025 and launched in January 2026. Additionally, Lilly is diversifying beyond GLP-1 into cardiovascular, oncology, and neuroscience, having announced several M&A deals in 2025 to broaden its therapeutic footprint.
AbbVie is positioned differently, primarily through its successful transition following the loss of exclusivity on Humira, which previously accounted for over 50% of revenues. Its immunology portfolio, consisting of Skyrizi and Rinvoq, generated combined sales of $26.0 billion in 2025 with growth exceeding 40%, and the company projects 2026 sales of more than $31 billion, slightly higher than its long-term guidance for 2027. Other segments are also performing well; neuroscience revenues rose nearly 20% to $10.8 billion in 2025 driven by Botox Therapeutic, Vraylar, Ubrelvy, and Qulipta, while oncology contributed $6.6 billion with contributions from Venclexta, Elahere, and Epkinly offsetting declines in Imbruvica. To fuel long-term growth, AbbVie has pursued an acquisition strategy, investing over $5 billion in 2025 to acquire assets in immunology, oncology, and neuroscience.
Despite strong fundamentals, both companies face distinct challenges that could impact their upside potential in 2026. Eli Lilly faces pressure from declining product prices in the United States, which is expected to drag top-line growth by low to mid-teens percentages in 2026, alongside rising competition in the GLP-1 diabetes and obesity market and flat-to-down sales for late-life cycle products like Trulicity, Taltz, and Verzenio. AbbVie continues to navigate the post-Humira landscape but relies on continued strong performance from Skyrizi and Rinvoq. Both companies maintain extensive global reach and diverse pipelines, making them attractive investment options, though Lilly appears more reliant on obesity growth while AbbVie has successfully diversified into aesthetics and eye care beyond its immunology core. The ultimate investment choice depends on weighing Lilly's explosive but potentially price-constrained GLP-1 momentum against AbbVie's robust diversification across multiple high-growth segments with a proven ability to replace blockbuster revenue losses.
๐ Eli Lilly GLP-1 drugs generated $36.5B in 2025 sales representing over half its revenue.
๐ผ AbbVie's Skyrizi and Rinvoq hit $26B combined sales, exceeding 2027 guidance for 2026.
๐ Both companies expect key drug growth despite price declines and legacy product revenue drops.
โก Lilly launches oral GLP-1 in Q2 2026; AbbVie acquired $5B+ assets to expand pipelines.
โ Strong balance sheets support both firms diversifying into neuroscience, oncology, and cardiovascular markets.
๐ The article compares Eli Lilly (LLY) and AbbVie (ABBV) as top contenders for investment upside in 2026.
๐ Eli Lilly's GLP-1 drugs Mounjaro and Zepbound generated $36.5 billion in 2025 sales, representing over half of its total revenue.
๐ Both companies' GLP-1 or other key drug sales are expected to continue growing into 2026 despite potential market headwinds.
๐ผ AbbVie successfully navigated Humira's patent loss with Skyrizi and Rinvoq, which generated $26 billion in 2025 combined sales.
๐ Lilly expects its approved pipeline drugs including orforglipron to drive further growth and offset declining legacy product revenues.
๐๏ธ Lilly plans to launch its oral GLP-1 pill orforglipron in the US during the second quarter of 2026 to compete with Novo Nordisk's recent oral Wegovy.
โ ๏ธ Price declines for Lilly's products in the US and rising competition are expected to impact top-line growth by a low to mid-teens percentage in 2026.
๐ฐ AbbVie expects combined Skyrizi and Rinvoq sales to exceed $31 billion in 2026, surpassing its long-term guidance target for 2027.
๐ง AbbVie's neuroscience portfolio drove revenue growth with nearly $20% increase to $10.8 billion in 2025 led by Botox and migraine drugs.
โ๏ธ Lilly is diversifying beyond obesity into cardiovascular, oncology, and neuroscience areas through M&A deals announced in 2025.
๐ฅ AbbVie acquired over $5 billion worth of early-stage assets in 2025 to bolster its immunology, oncology, and neuroscience pipelines.
๐ Both companies face legacy product declines but maintain strong balance sheets and global reach across key therapeutic areas.
๐งฌ Lilly is developing retatrutide, a triple-acting incretin for obesity and diabetes, alongside other indications in late-stage studies.
โ๏ธ AbbVie's oncology segment grew 1.5% year-over-year to $6.6 billion in 2025 despite some decline in key product Imbruvica sales.
๐ Both firms have extensive global operations with strong presence in immunology, oncology, and neuroscience markets.
Bullish Signals
Skyrizi and Rinvoq generated $26.0 billion in 2025 sales with over 40% growth.
Combined Skyrizi/Rinvoq 2026 sales expected to exceed $31 billion targets.
Neuroscience portfolio sales surged nearly 20% to $10.8 billion in 2025.
On oncology generated $6.6 billion in 2025, up 1.5% year over year.
AbbVie invested over $5 billion in 2025 acquisitions for long-term pipeline growth.
Lilly's new drugs including Mounjaro and Ebglyss will drive 2026 sales.
Multiple Lilly therapies like Kisunla and Omvoh recently received regulatory approvals.
Lilly's orforglipron oral GLP-1 launches Q2 2026 as injectable alternative.
Risk Factors
Declining US drug prices expected to drag growth by low-mid teens in 2026.
Late-cycle sales of Trulicity, Taltz, and Verzenio projected flat or down in 2026.
Novo Nordisk's oral Wegovy approval may erode Lilly market share before forglipron launches Q2 2026.
Rising GLP-1 competition threatens growth trajectories for Mounjaro and Zepbound.
AbbVie expects $31B combined 2026 sales to miss both own and 2027 guidance.
Bullish Signals
AbbVie successfully navigated Humira loss of exclusivity by launching two highly successful immunology medicines, Skyrizi and Rinvoq, which generated combined sales of $26.0 billion in 2025 with year-over-year growth of more than 40%.
In 2026, AbbVie expects combined Skyrizi and Rinvoq sales of more than $31 billion, exceeding its long-term guidance targets and signaling strong product momentum.
AbbVie's neuroscience portfolio contributed robust growth with sales increasing almost 20% to $10.8 billion in 2025, driven by Botox Therapeutic, Vraylar, Ubrelvy, and Qulipta.
The oncology segment generated combined revenues of $6.6 billion in 2025, up 1.5% year over year, supported by higher sales of Venclexta and new drugs Elahere and Epkinly.
AbbVie has invested more than $5 billion in 2025 on acquisitions to bolster its early-stage pipeline in immunology, oncology, and neuroscience areas for long-term growth.
Eli Lilly expects its new drug portfolio including Mounjaro, Zepbound, Ebglyss, Jaypirca, Kisunla, Omvoh, and Inluriyo to drive sales growth in 2026.
Lilly secured approvals for several new therapies such as Omvoh, Jaypirca, Ebglyss and Kisunla over the past few years, all contributing to revenue expansion.
Lilly's once-daily oral GLP-1 small molecule orforglipron is expected to launch in the United States during the second quarter of 2026, offering a convenient alternative to injectable treatments.
AbbVie and Lilly both maintain strong R&D pipelines, significant market capitalizations, and extensive global reach across key therapeutic areas like immunology, oncology, and neuroscience.
Risk Factors
Lilly faces a significant headwind from declining product prices in the United States, with price erosion expected to continue dragging on top-line growth by a low to mid-teens percentage in 2026.
Sales of late-life cycle products including Trulicity, Taltz, and Verzenio are projected to be flat or decline in 2026 as competition intensifies.
Novo Nordisk's approval of an oral version of Wegovy in December 2025 gives the rival first-to-market advantage, potentially eroding Lilly's market share and revenues before its own oral obesity pill, orforglipron, launches in the second quarter of 2026.
Rising competition in the GLP-1 diabetes and obesity market is identified as a key headwind that could impact growth trajectories for Lilly's blockbuster Mounjaro and Zepbound.
AbbVie may face revenue challenges despite strong Skyrizi and Rinvoq sales, as it expects 2026 combined sales of $31 billion to fall short of its own long-term guidance, which also stands at $31 billion for 2027.
The article argues that AbbVie (NYSE: ABBV) is a strong defensive investment suitable for holding during market downturns, citing its resilient business model and deep product pipeline. The text explains that AbbVie's vast portfolio of medicines for chronic autoimmune conditions and cancer maintains consistent revenue even if prescription volumes soften in an economic slowdown. Furthermore, the company utilizes a robust development pipeline to successfully navigate the "patent cliff," ensuring long-term value creation despite losing protection on older blockbuster drugs.
A key highlight of the investment case is AbbVie's status as a Dividend King, having increased its payout for over 50 consecutive years. The article emphasizes that this streak indicates management's commitment to maintaining dividends even during challenging times, which can help smooth out losses for investors when equity markets crash. While it warns against speculative biotechs, it positions AbbVie as a high-quality, resilient option distinct from companies with no products or consistent net losses.
The piece contextualizes these points by also recommending Microsoft (NASDAQ: MSFT) as a similarly defensive technology stock due to its entrenched software products and strong credit rating. It notes that while Azure growth could moderate in a recession, the company's leadership in cloud computing and AI offers attractive long-term prospects for patient investors who might buy at a discount.
The article concludes with an advertisement segment from The Motley Fool Stock Advisor, which claims their 10 best stocks list did not include AbbVie despite their team holding a position in the company. It uses historical examples of Netflix and Nvidia to illustrate the potential returns of following their specific picks, ultimately urging readers to consider joining their community for updated recommendations.
โ Defensive pharma and tech stocks are highlighted for stability during market volatility.
๐๐ป AbbVie offers patent diversification while Microsoft provides reliable recurring revenue from productivity tools.
๐ The Motley Fool's Stock Advisor has historically delivered massive returns significantly outperforming the S&P 500.
๐ Markets face volatility due to geopolitical tensions and tariff uncertainty, prompting investors to seek defensive assets.
๐ AbbVie is highlighted as a resilient pharmaceutical stock with a strong portfolio in chronic autoimmune conditions and cancer therapies.
๐ก๏ธ Pharma stocks are generally considered defensive because demand for essential medicines remains stable during economic slowdowns.
๐ AbbVie has a deep product pipeline that helps mitigate risks associated with patent cliff expiration.
๐ The company is a "Dividend King," having increased its dividend payouts for 50 consecutive years, which helps smooth investor losses during downturns.
๐ป Microsoft is presented as a defensive tech stock due to its entrenched products like Office used daily by individuals and businesses.
โ๏ธ While Azure is a growth engine, the company maintains consistent revenue from productivity tools even if clients tighten budgets in a recession.
โญ Microsoft holds an Aaa credit rating, which is higher than that of the U.S. government, signaling rock-solid financial health.
๐ Investors may buy Microsoft at a discount during downturns, expecting it to recover and deliver superior long-term returns as before.
โ ๏ธ AbbVie was notably excluded from The Motley Fool's current list of top 10 stocks recommended by the Stock Advisor team.
๐ The Stock Advisor report highlights massive historical returns for past picks like Netflix (52x return) and Nvidia (113x return).
๐ The average total return for the Stock Advisor service is reported at 952%, significantly outperforming the S&P 500's 191%.
โณ All Stock Advisor returns cited are noted as of March 11, 2026.
๐งโ๐ผ Prosper Junior Bakiny holds no position in the mentioned stocks, while The Motley Fool itself recommends AbbVie and Microsoft.
Bullish Signals
AbbVie (NYSE: ABBV) is a 'Dividend King' with 50 years of payout increases.
Its portfolio targets resilient chronic autoimmune and cancer markets.
A deep pipeline offers strategies to navigate the patent cliff.
As a defensive stock, it generates consistent revenue during volatility.
AbbVie excluded from Motley Fool's top 10 stocks list.
Dividends may not offset losses during severe market crashes.
Azure growth could moderate if clients tighten recession budgets.
Microsoft may fall sharply with the broader market in a downturn.
AbbVie prescription volumes may soften during challenging economic periods.
Bullish Signals
AbbVie (NYSE: ABBV) is highlighted as a 'Dividend King' with 50 straight years of payout increases, providing income stability during market downturns.
The company possesses a vast pharmaceutical portfolio focused on chronic autoimmune conditions and cancer, sectors which tend to remain resilient even when prescription volumes soften.
AbbVie has a deep pipeline that allows it to develop and launch new products, offering a strategic way to navigate the patent cliff.
As a defensive stock, AbbVie is positioned to generate consistent revenue and earnings even during severe economic problems or market volatility.
The Motley Fool has identified AbbVie as a top stock for investors to prepare for a market downturn, specifically noting its defensive nature against cyclical exposure.
Risk Factors
Equity markets have been volatile this year, with some fear the stock market could take a turn for the worse by the end of the year amid geopolitical tensions and lingering tariff-related uncertainty.
The article explicitly states that AbbVie was not included in the Motley Fool Stock Advisor's list of 10 best stocks to buy now, potentially implying it is not among their top tier of high-conviction picks.
While AbbVie's dividend status as a Dividend King is noted as positive, dividends may not be sufficient to offset losses if the company faces severe challenges or market crashes that impact its payout ability.
Microsoft's Azure segment could see growth moderate if clients tighten budgets during a recession, indicating potential downside pressure on its primary growth engine.
The article acknowledges that Microsoft is unlikely to emerge entirely unscathed from an economic downturn, with the possibility of falling sharply along with the rest of the market before recovering.
Prescription volumes for AbbVie may soften during challenging periods, which could impact consistent revenue generation despite strong demand in specific therapeutic areas.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)